Global X S&P Biotech ETF (ASX:CURE)

Assets	48.30M
Expense Ratio	0.45%
PE Ratio	33.58
Forward PE	17.59
Dividend (ttm)	n/a
Dividend Yield	n/a
Ex-Dividend Date	n/a
Payout Frequency	n/a
Payout Ratio	n/a

Volume	1,196
Open	76.52
Previous Close	76.50
Day's Range	76.21 - 76.99
52-Week Low	56.29
52-Week High	81.49
Beta	0.32
Holdings	10
Inception Date	Nov 8, 2018

About CURE

The Global X S&P Biotech ETF, identified by its ticker CURE, endeavors to replicate the overall financial performance, encompassing both capital gains and dividends, of the S&P Biotechnology Select Industry Index, before any management fees and operational costs are deducted.

• Asset Class: Equity
• Category: Health Care
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: CURE
• Provider: Global X
• Index Tracked: S&P Biotechnology Select Industry

Performance

CURE had a total return of 32.40% in the past year, including dividends. Since the fund's inception, the average annual return has been 8.80%.

Top Holdings

17.77% of assets

Name	Symbol	Weight
Moderna, Inc.	MRNA	2.27%
Twist Bioscience Corporation	TWST	1.99%
Natera, Inc.	NTRA	1.85%
Halozyme Therapeutics, Inc.	HALO	1.74%
Biogen Inc.	BIIB	1.67%
United Therapeutics Corporation	UTHR	1.67%
Amgen Inc.	AMGN	1.66%
Spyre Therapeutics, Inc.	SYRE	1.65%
AbbVie Inc.	ABBV	1.64%
Exelixis, Inc.	EXEL	1.64%

Data Sources: S&P Global Market Intelligence, Financial Modeling Prep, and more

Historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep. Several fund data points are also provided by Finnhub.

Last checked:

Oct 30, 2026

Data Sources Report a data error